On October 28, 2025, Edesa Biotech, Inc. (EDSA) announced positive results from a Phase 3 clinical trial evaluating paridiprubart (EB05) as a treatment for Acute Respiratory Distress Syndrome (ARDS). EB05 met both the primary and secondary endpoints of the study, which included a statistically significant and clinically meaningful 25% relative risk reduction in the risk of death compared to placebo (P<0.001). Across the 275 patients that were enrolled for the Phase 2 and Phase 3 studies, EB05 was generally well-tolerated and consistent with the observed safety profile to date. The company plans to submit data to regulatory agencies to determine the next steps for the program.
